Meanwhile, the fact that the GLUT4 protein expression in both adipose and skeletal muscle was siginicantly enhanced by FYGL treatment may be also related to the anti-obesity effect of FYGL since increase of adipose and skeletal muscle glucose disposal can attribute to the alleviation of fat accumulation. The gene discussed is SLC2A4; the disease is obesity disorder.